Antibacterial agent 356
Antibacterial agent 356 is an orally active antibacterial agent. Antibacterial agent 356 binds to the Mrr1 transcription factor, inhibits the expression of the MDR1 efflux pump gene, reduces the efflux of Rhodamine 123, and increases the accumulation of intracellular substrates in drug-resistant Candida albicans cells. Antibacterial agent 356 induces mitochondrial membrane potential reduction and ROS accumulation in Candida albicans, inhibits the yeast-hypha transition process, and suppresses its biofilm formation. Antibacterial agent 356 reverses efflux pump-mediated drug resistance in azole-resistant Candida albicans with overexpressed Mdr1. Antibacterial agent 356 improves the survival rate of Galleria mellonella larvae infected with azole-resistant Candida albicans*CA632, and reduces the renal fungal load and renal tissue damage in infected BALB/c mice. Antibacterial agent 356 can be used for the research of Candida albicans infection.
For research use only. We do not sell to patients.
- Formula: C14H9F2NO2S
- Molecular Weight:293.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Antibacterial agent 356 (compound 6AO) exhibits selective in vitro antifungal and antibacterial activity, with potent inhibition of Staphylococcus aureus (MIC 0.4 μM) and moderate activity against Candida albicans and Cryptococcus neoformans, but no activity against Aspergillus fumigatus, Escherichia coli, or Pseudomonas aeruginosa[1].
Antibacterial agent 356 synergizes with multiple azole drugs to reverse azole resistance in Mdr1-overexpressing Candida albicans CA632 and G5, shows additive activity against Cdr1/Cdr2-overexpressing strains, and has no activity against drug-resistant Candida auris[1].
Antibacterial agent 356 (27.3-109.2 μM; 6 h) inhibits efflux pump function in drug-resistant Candida albicans CA632 by downregulating efflux pump gene expression, particularly MDR1, and enhances the suppressive effect of Fluconazole (HY-B0101) on MDR1 expression[1].
Antibacterial agent 356 (13.7-218.4 μM; 24 h) exhibits concentration-dependent antifungal activity against Candida albicans SC5314, with fungicidal effects at 218.4 μM and fungistatic effects at 109.2 μM[1].
Antibacterial agent 356 (54.6-218.4 μM; 3-6 h) induces mitochondrial dysfunction in Candida albicans SC5314, characterized by dose-dependent loss of membrane potential and excessive ROS accumulation at intermediate concentrations[1].
Antibacterial agent 356 (13.7-218.4 μM; 6 h) inhibits yeast-to-hyphal transition in Candida albicans SC5314[1].
Antibacterial agent 356 (54.6-436.8 μM) potently inhibits biofilm formation in Candida albicans SC5314 in a dose-dependent manner[1].
Antibacterial agent 356 (1-100 μM; 48 h) exhibits minimal cytotoxicity against human normal hepatocytes (L02) at concentrations up to 100 μM[1].
Antibacterial agent 356 (24 days) has a low propensity to induce resistance in Candida albicans SC5314[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human normal hepatocytes (L02)
-
Concentration:1 μM, 10 μM, 20 μM, 50 μM, 80 μM, 100 μM
-
Incubation Time:48 h
-
Result:Maintained cell viability above 80% across all tested concentrations, with minimal cytotoxicity relative to the blank group.
In Vivo
Antibacterial agent 356 (5-10 mg/kg; oral gavage; daily; 6 days) reduces kidney fungal burden and renal tissue damage in immunocompromised BALB/c mice infected with azole-resistant C. albicans CA632, with a significantly greater effect observed when combined with 5 mg/kg Fluconazole[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:larvae (~0.25 g, free of melanization)[1]
-
Dosage:2400 ng/larvae; 3200 ng/larvae; 3200 ng/larvae + 800 ng/larvae fluconazole
-
Administration:intrahemocoel injection; single dose
-
Result:Elevated larval survival versus vehicle controls (3200 ng/larvae monotherapy).
Decreased melanized nodule size and count relative to untreated infected groups (3200 ng/larvae monotherapy).
Boosted larval survival and lowered melanized nodule burden far more potently than 3200 ng/larvae monotherapy (3200 ng/larvae + 800 ng/larvae fluconazole combination).
-
Animal Model:BALB/c (female, 4-6 weeks old, 18-20 g, cyclophosphamide-induced immunosuppression)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 10 mg/kg + 5 mg/kg fluconazole
-
Administration:oral gavage; daily; 6 days
-
Result:Reduced renal fungal loads relative to vehicle controls (10 mg/kg monotherapy).
Lessened fungal abundance and alleviated fungal-triggered renal lesions versus untreated infected groups (10 mg/kg monotherapy).
Markedly cut renal fungal loads and mitigated renal tissue injury superior to 10 mg/kg monotherapy, with intact, tightly arranged renal tubular epithelia (10 mg/kg + 5 mg/kg fluconazole combination).
Chemical Information
-
Molecular Weight 293.29
-
Formula C14H9F2NO2S
-
SMILES
FC1=CC(F)=C(C=C1)C(C2=NOC(C2)C3=CC=CS3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Nuclear Protein Extraction (High-Salt/Hypotonic Fractionation)
The high-salt/hypotonic fractionation method for nuclear protein extraction is based on the differential solubility of cellular components. Cytoplasmic proteins are extracted first using a hypotonic buffer that causes cell swelling and membrane rupture, followed by centrifugation to separate the cytoplasmic supernatant from the nuclear pellet. The nuclear pellet is then subjected to high-salt extraction (e. g. , 0. 4 M (NH4)2SO4 or 1 M NaCl) to solubilize tightly bound nuclear matrix proteins, including transcription factors, histones, and structural proteins associated with chromatin and the nuclear scaffold. This approach allows for the isolation of both soluble cytoplasmic proteins and salt-resistant nuclear proteins while minimizing cross-contamination.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Fungal Biofilm Culture
Fungal biofilm culture is an in vitro method for growing surface-attached fungal communities, most commonly Candida albicans, on abiotic substrates such as polystyrene wells, silicone elastomer, or polymethylmethacrylate; the assay models adhesion, proliferation, filamentation, extracellular-matrix-associated maturation, and dispersion. Biofilm output can be read by optical density at 600 nm for adherent biomass, XTT reduction for metabolic activity, CFU recovery for viable attached or dispersed cells, and microscopy for architecture.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Antibacterial agent 356
- Antibacterial agent356
- Antibacterial agent-356
- Bacterial
- P-glycoprotein
- Reactive Oxygen Species (ROS)
- Rhodamine 123
- MDR1 efflux pump
- fluconazole
- BALB/c mice
- Staphylococcus aureus
- Candida albicans
- mitochondrial dysfunction
- Mrr1 transcription factor
- biofilm formation
- Galleria mellonella larvae
- Inhibitor
- inhibitor
- inhibit